# A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)

> **NCT01760460** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 307 (actual)

## Conditions studied

- Dyslipidemia

## Interventions

- **DRUG:** Anacetrapib
- **DRUG:** Placebo for anacetrapib

## Key facts

- **NCT ID:** NCT01760460
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-14
- **Primary completion:** 2015-03-04
- **Final completion:** 2015-03-04
- **Target enrollment:** 307 (ACTUAL)
- **Last updated:** 2017-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01760460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01760460, "A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01760460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*